Related Experiment Video
Updated: Nov 7, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Cannabidiol Treatment Results in a Common Gene Expression Response Across Aggressive Cancer Cells from Various
Pierre-Yves Desprez1, Ryuichi Murase1, Chandani Limbad1
1California Pacific Medical Center, Research Institute, San Francisco, California, USA.
Abstract:
Background: We previously reported that cannabidiol (CBD), a cannabinoid with a low toxicity profile, downregulated the expression of the prometastatic gene inhibitor of DNA binding 1 (ID1) in cancer cells, leading to inhibition of tumor progression in vivo. While CBD is broadly used, including in the self-medication of cancer patients, and CBD-based therapies are undergoing clinical evaluation for cancer treatment, its mechanisms of action are still poorly understood. Methods: In this study, using microarray analysis and Western blot analysis for validation, we attempted to identify the full spectrum of genes regulated by CBD across various aggressive cancer cell lines, including the breast, brain, head and neck, and prostate. Results: We confirmed that ID1 was a major target downregulated by CBD and also discovered that CBD inhibited FOXM1 (Forkhead box M1), a transcriptional activator involved in cell proliferation, while simultaneously upregulating GDF15 (growth differentiation factor 15), a cytokine associated with tissue differentiation. Conclusion: Our results suggest that, by modulating expression of shared key cancer-driving genes, CBD could represent a promising nontoxic therapeutic for treating tumors of various origins.
Insights
Cannabidiol (CBD) downregulates key cancer genes like ID1 and FOXM1, while upregulating GDF15. This suggests CBD is a promising, non-toxic therapy for various tumor types.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cannabidiol (CBD), a non-toxic cannabinoid, previously showed downregulation of the prometastatic gene ID1, inhibiting tumor progression.
- Understanding CBD's mechanisms is crucial as it's used for self-medication and clinical cancer trials.
Purpose of the Study:
- To identify the full spectrum of genes regulated by CBD in aggressive cancer cell lines.
- To further elucidate the molecular mechanisms underlying CBD's anti-cancer effects.
Main Methods:
- Microarray analysis to screen gene expression changes induced by CBD.
- Western blot analysis for validation of key gene expression alterations.
Main Results:
- Confirmed CBD downregulates inhibitor of DNA binding 1 (ID1) expression.
- Identified CBD inhibition of FOXM1 (Forkhead box M1) and upregulation of GDF15 (growth differentiation factor 15).
Conclusions:
- CBD modulates key cancer-driving genes, including ID1, FOXM1, and GDF15.
- These findings support CBD as a potential non-toxic therapeutic agent for diverse cancer types.
Related Concept Videos
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer

